Site-specific glycosylation analysis (i.e. glycopeptide analysis) allows for glycoform-by-glycoform characterization of antibodies. Glycopeptide analysis maintains linkage information of where the glycan is attached to and allows for mapping of the microheterogeneity at each glycosylation site. Site-specific glycosylation analysis can allow manufacturers and regulators to better evaluate and control site-specific product quality attributes during biosimilar development and quality control. While bulk glycan analysis methods provide the percentage of total glycans present in a sample, site-specific glycosylation analysis determines what glycoforms are present at each site.
Site-specific glycosylation can have effects on mAb efficacy, stability and safety profiles. For this reason, further characterization beyond aggregate measurements should be performed to detail site specific glycosylation. Glycosylation landscape at each Asn residue will influence interaction with immune receptors as well as complement activation and clearance. Site-specific glycosylation is important for predictable clinical performance and demonstrating biosimilarity.
Effect of N-glycosylation on IgA antibody functions.1,5
Fc glycosylation takes place at Asn297 within the CH2 domain of the Fc region. N-linked glycosylation at this position is one of the quality attributes which determines antibody effector function and structure. The oligosaccharide found here is a biantennary complex type, and its role is thought to maintain an open conformation of the Fc region allowing immune effector cell receptor binding. The level of core fucose on this glycan can modulate affinity to Fcγ receptors and impacts antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. The number of terminal galactoses impact binding to C1q and can impact complement-dependent cytotoxicity (CDC). The glycosylation site at N297 is closely regulated by guidelines, as varying amounts of fucose, galactose, or sialic acid may alter the efficacy of the antibody.
Table 1 Impact of Fc N297 Glycosylation on Antibody Functions
| Glycan Feature | Structural Effect | Functional Consequence |
| Core fucose | Restricts FcγRIIIa accessibility | Modulates ADCC potency |
| Terminal galactose | Enhances C1q binding affinity | Influences CDC activity |
| Sialic acid | Alters Fc conformation | Modulates anti-inflammatory signaling |
| High mannose | Accelerates clearance | Reduces serum half-life |
Antibody glycosylation also affects their stability, pharmacokinetics, and antigenicity in ways other than affinity alteration. Glycans at N297 sterically separate the CH2 domains and contribute to heat stability. Deglycosylation or mutation at this site often results in aggregation or mis-folding. Antibodies with high-mannose glycans are recognized by the mannose receptor and are rapidly cleared by the liver. Antibodies lacking terminal sialic acids and galactoses (on complex glycans) have been demonstrated to have reduced half-life (as they have lower affinity for the neonatal Fc receptor). Antibodies displaying glycans that are non-human in origin, or otherwise have aberrant glycosylation motifs have also been shown to be antigenic. For this reason it is critical to monitor glycosylation.
Traditional released glycan analysis involves enzymatic release of glycans from their protein backbone. The resultant compositional data provides no information regarding glycan attachment site. Such an approach is often insufficient to characterize glycans on multi-domain antibodies and fusion proteins, which may have glycosylation at multiple sites. Site-specific microheterogeneity may exist between glycans at different attachment sites, and released glycan analysis cannot determine which glycoforms are from the Fc versus Fab domains or another portion of the protein. This information can be important quality attributes which have implications for function. Protein-glycan stoichiometry and site occupancy is also lost during released glycan analysis, both of which contribute to bioactivity. Glycopeptide mapping maintains the linkage between glycan and peptide, allowing localization of every glycoform.
Site-specific glycan analysis by glycopeptide MS refers to mass spectrometry-based characterization of glycopeptides which maintains site-specific information lost during released glycan analysis. Site-specific glycan analysis will reveal which glycans reside on which glycosylation sites and allows the assessment of microheterogeneity as well as characterization of important structure-function relationship for characterization of biopharmaceuticals and biosimilar comparability exercises.
Glycopeptide-based workflows typically start with proteolysis of the mAb to produce peptides containing the glycosylation sites. The peptides are separated by LC, usually reversed-phase or HILIC. The eluting glycopeptides are analyzed by tandem mass spectrometry, where fragmentation is induced by collision-induced dissociation or electron transfer dissociation. Assignment of glycan occupancy and microheterogeneity at each glycosylation site can be achieved unambiguously by interpreting specific fragment ions that report the peptide backbone and glycan identity with high sensitivity and specificity.
Site-specific glycopeptide quantitation also provides access to abundance of each glycoform at each site allowing for detailed profiles of glycosylation heterogeneity including overall distribution from high mannose through complex type glycans with neutral and acidic terminal residues. Site-specific quantitation provides access to less abundant glycans that may be present at very low levels at a particular site, such as afucosylated glycans that may have much higher biological activity such as ADCC. This low abundant glycan can be very important when trying to show batch to batch consistency as well as site specific glycosylation comparisons for approval of biosimilars.
Advantages of glycopeptide analysis versus other strategies: Site specific structural information allows correlation of structure to function on a per glycosylation site basis. This is an advantage over analysis of released glycans which cannot retain any linkage information. Additionally, although intact mass approaches allow quantitation of glycoform distributions within a sample, they offer limited ability to elucidate structure at higher resolutions and therefore suffer from ambiguities when deducing microheterogeneity on a site-specific basis. Glycopeptide mapping overcomes these limitations allowing confident assignments of site specific glycan microheterogeneity while offering improved structural resolution for more directly correlating structure to function (i.e. binding to a receptor or activation of complement) and better enabling comparisons.
Glycopeptide analysis is employed during innovator monoclonal antibody development as a powerful analytical tool used to characterize site-specific glycosylation aiding in candidate selection as well as process development and optimization, manufacturing consistency, and regulatory filings. Glycopeptide analysis offers structural information required to verify glycosylation meets expectations based on mechanism of action and is maintained during development.
Overview of the experimental strategy and molecular structure of Infliximab.2,5
Aside from aiding early on during the candidate selection process, glycopeptide analysis can also help identify potential glycosylation issues. Predicting site-specific variations that could affect drug activity or product stability. Site-specific glycopeptide analysis can also aid efforts in Fc engineering by directly elucidating how mutations alter glycan processing. This would enable rational engineering to improve specific effector functions while removing unwanted glycoforms. Early detection of problematic glycosylation, such as high mannose or xenoreactive epitopes, enables us to modify the molecular structure, preventing future glycosylation issues and accelerating regulatory approval.
With glycopeptide analysis during process development, understanding of the impact of media composition and culture conditions on site-specific glycosylation can be gained allowing mechanistic insight into effects from upstream parameters. Bioreactor conditions can then be optimized in a data-driven manner to steer glycoform distributions toward an ideal product feature set. For example, galactosylation may be increased for decreased complement activation or fucosylation may be minimized for improved effector function. Adjustment of process parameters can then be used to finetune glycosylation on a site-specific level to exert control over glycosylation as it relates to critical quality attributes remaining within set acceptance ranges during scale up for manufacturing.
Site-specific glycopeptide analysis is useful for batch-to-batch manufacturing reproducibility. Comparing glycopeptide maps from different production batches allow stringent monitoring of glycosylation pattern. Since glycopeptide analysis allows detection of small changes in glycoform distribution that may be undetected by glycan profiling alone, it also allows process control adjustments to be made early if changes are observed. Glycopeptide mapping can also be used during stability studies to determine if any glycans are degraded or remodeled over time.
Glycopeptide analysis is an analytical technique commonly used in biosimilar characterization to provide site-specific comparison of glycosylation between candidate products and reference products. Glycopeptide analysis can help fulfill guidelines requiring thorough structural characterization and analytical similarity between reference and candidate products to facilitate stepwise biosimilar development potentially allowing avoidance of clinical studies if high analytical similarity is shown.
Table 2 Glycopeptide Analysis Applications in Biosimilar Development
| Development Phase | Regulatory Focus | Glycopeptide Analysis Role | Strategic Value |
| Analytical characterization | Structural similarity | Site-specific profile comparison | Establishes high similarity foundation |
| Risk assessment | Functional impact | Microheterogeneity correlation | Identifies critical quality attributes |
| Biosimilarity demonstration | Acceptable variability | Statistical comparison | Supports reduced clinical data needs |
FDA, EMA and other regulatory agencies have placed great emphasis on glycosylation for protein therapeutics and now mandates thorough glycosylation assessment for the approval of biosimilars. Given the regulatory guidelines' totality-of-evidence framework for biosimilar approval, characterizing glycosylation at the site-specific level is crucial, not just evaluating overall glycan profiles. Additionally, sponsors should demonstrate that the variability of glycosylation seen with the biosimilar falls within that of the reference product at each site as glycosylation can differ among sites on a protein and alter biological activity even if overall glycosylation appears similar.
Characterization of glycopeptides enables site-resolved analysis of Fc glycosylation. Glycopeptide analysis can therefore be directly compared between a biosimilar candidate and the reference product. At the glycopeptide level, characterization of glycosylation provides information about the distribution of glycoforms at each glycosylation site on the protein. Glycopeptide analysis can even reveal minor alterations in afucosylation, galactosylation, or sialylation that may be undetectable by aggregation, but which can affect effector function. Detection of low abundant glycoform variants unique to each site allows for the sensitivity needed to either confirm high analytical similarity or uncover substantial differences that warrant further investigation.
To aid in risk assessment, glycopeptide mapping can allow correlation of glycosylation at specific sites with functional activity, such as antibody-dependent cell cytotoxicity. Site specific glycopeptide mapping allows differentiation between meaningful differences in glycans versus acceptable microheterogeneity by correlating known effector functions with specific site-glycan combinations. Identifying ranges of acceptable variability involves defining what glycan modifications matter clinically and therefore what constitutes a meaningful acceptance criterion for sponsors.
Stepwise development takes advantage of the extensive analytical characterization described above to argue for smaller clinical studies. Glycopeptide analysis is one part of the analytical similarity assessment. By proving highly similar site-specific glycosylation using orthogonal mass spectrometric techniques, a demonstration of structural sameness can be used to argue for a stepwise approach to clinical development. Guidance states "...as the analytical demonstration of biosimilarity reduces residual uncertainty, the need for further clinical studies can be minimized when a robust assessment of physicochemical and biological characteristics can adequately support approval." Thus data packages show that the biosimilar is the same as the reference product for important quality attributes.
Enhanced mass spectrometric techniques for antibody glycopeptide analysis generally rely upon ultra-high resolution mass spectrometers, sample enrichment strategies, bioinformatics pipelines, and validation studies that allow for confident, sensitive and reproducible quantification of site-specific glycosylation.
Ultra-high resolution LC-MS/MS instruments, such as Orbitrap or quadrupole-time-of-flight (Q-TOF), provide mass accuracy and resolution to unequivocally identify glycopeptides. Such instruments can resolve glycoforms that differ by a single monosaccharide residue or other small mass differences. Combined collisional dissociation (CD) and electron transfer dissociation (ETD) fragmentation can be used to reveal complementary structural information. CD sequencing will identify glycan composition, while ETD fragmentation maintains glycan-peptide connectivity allowing for full site-specific glycan identification.
Enzymes such as trypsin are used in digestion workflows to produce glycopeptides with favorable chromatography characteristics. Alternative enzymes such as Glu-C or immunoglobulin-degrading enzymes can be used to produce shorter or longer peptides, providing greater coverage. Fractionation strategies may also enrich for low abundant glycopeptides that would otherwise be missed. Hydrophilic interaction chromatography, or enrichment via lectin affinity can be used to enrich low abundance species allowing for the representation of glycan microheterogeneity at each site.
Sophisticated workflows will feature automated search engines that can identify experimental spectra by querying glycopeptide spectral libraries. Automated approaches facilitate data analysis for larger samples sets. Manual inspection of key spectra should always be performed to verify glycan structures and site assignments. Relative and semi-quantitative comparisons allow users to evaluate glycoform distributions across samples for purposes such as ensuring batch-to-batch uniformity or statistically comparing biosimilars.
Method qualification experiments determine performance characteristics such as the limit of detection (LOD) and the range of linearity by testing against appropriate reference materials. The reproducibility of the method during a typical analytical run can be determined by doing a within-batch study. The between-batch study demonstrates that the glycopeptide method produces reproducible results between days, analysts, and reagent batches. Validation ensures that the glycopeptide method is suitable for determining and reporting site-specific glycosylation.
Applications can be found in any antibody format. Whether looking at IgG1, IgG2, IgG3, IgG4, IgA, IgE or custom engineered antibodies and antibody fragments like Fabs, Fcab, bispecific antibodies, multivalent antibodies or heavy-chain-only antibodies, glycopeptides are the common denominator that allow analysts to interrogate glycosylation sites independently of one another.
Profiling of glycopeptides allows subclass-specific glycosylation patterns to be characterized since IgG1, IgG2 and IgG4 have different glycoform distribution and effector function potentials, although all three subclasses share the N297 glycosylation site. For instance IgG1 antibodies are often more galactosylated and sialylated than IgG2 and IgG4, resulting in a stronger ability to activate complement, while IgG2 has more heterogeneity in glycosylation that can influence binding to Fc receptors and IgG4 has distinct bisection patterns which can influence anti-inflammatory activity. Site-specific glycosylation profiling allows these differences to be resolved, which is critical for candidate selection and biosimilar development if the reference product is of a specific IgG subclass.
Bispecific antibodies offer glycosylation considerations due to their format consisting of two antigen-binding sites and possible asymmetry. Bispecific antibodies can contain several glycosylation sites which may have different microenvironments surrounding them. Glycopeptide analysis offers site resolution which can confirm uniform processing between engineered heavy and light chains for bispecific antibodies. Glycopeptide analysis allows confidence that glycosylation at each site, such as antigen binding sites or Fc regions, support structural integrity and desired function. Glycopeptide analysis can reveal any changes in glycan profiles that may occur due to asymmetry that may impact functions like recruitment of immune cells or stability. Ensuring similarity of glycosylation between different production runs can aid in consistent manufacturing of these modalities as bulk glycan would not distinguish differences between glycosylation sites.
Fc-fusion proteins are therapeutic proteins comprised of immunoglobulin Fc regions fused to another protein or peptide. As a result, they display a complex glycosylation profile consisting of glycans across domains. Glycopeptide analysis allows characterization of glycosylation domain-by-domain. For Fc-fusions this can allow separation of glycosylation occurring on the Fc region vs the fused protein partner which may contain additional N- or O-linked glycans. Analyzing domain specific glycosylation can be critical for proving lot-to-lot consistency as well as biosimilarity. The glycosylation on each domain can affect PK, immunogenicity, and activity independently and may need to be monitored and controlled separately.
Analysis of glycopeptides remains the gold standard analytical method to confirm removal of core fucose and define the glycoform profile for engineered afucosylated antibodies. Quantitative information on N297 afucosylation can be obtained along with detection of contaminating fucosylated forms that may negatively impact increased efficacy. Additionally, increases in galactosylation or sialylation that may occur as a result of glycoengineering can also be assessed through analysis of glycopeptides. Confirmation of glycoengineering at the protein level ensures that desired modifications have been reached to aid in process development and quality control of engineered antibodies for improved ADCC target killing.
Reports generated from glycopeptide analysis represent recorded information of site-specific antibody glycosylation. Glycopeptide analysis report translates analytical results into formal deliverables for product development and regulatory filings. Glycopeptide reports provide the basis for making informed decisions about process robustness, structural analysis, and biosimilarity evaluation.
Site-specific glycosylation maps graphically illustrate glycan microheterogeneity site by site (i.e., at each glycosylation site throughout the antibody molecule). This deliverable typically includes both graphical depictions as well as tabulated representations of the relative distribution of glycoforms ranging from high-mannose to complex across individual glycosylation sites (i.e., glycoforms linked to specific asparagine residues). As a result, these maps allow for rapid determination of site occupancy and processing uniformity. Site-specificity of glycans allows the glycan structures to be linked to amino acid sequence position allowing linkage to functional assays and comparability to biosimilar candidates.
Relative Fc glycoform quantification involves measuring the percentage of various glycoforms present at the invariant N297 glycosylation site. This type of analysis can be useful for determining critical quality attributes. Relative abundance of afucosylated, galactosylated, and sialylated glycans can be determined by integration of extracted ion chromatograms or spectral counting and used to track lot-to-lot variability or process control. Relative quantitation allows specifications for product glycoform content to be developed.
Documented tandem mass spectra including assignment of fragment ions provide proof for glycopeptide structure assignment. The spectrum will show glycosidic bond fragments which confirm carbohydrate composition as well as peptide backbone fragments which confirm amino acid sequence and glycosylation site assignments. The spectrum is often annotated with oxonium ions, Y and B fragments from the glycan, and b/y ions from the peptide portions, providing documentation for structure deductions. These spectra are annotated with the interpreted fragmentations and are used as supplemental information in regulatory filings to substantiate glycoform assignments.
Regulatory-ready technical reports bring together results from glycopeptide characterization experiments into formats designed for inclusion in chemistry, manufacturing and controls portions of investigational new drug applications (IND) and biologics license applications (BLA). Such reports should include descriptions of methods used, sample treatment, instrument settings, thresholds and any other information needed to completely understand how samples were characterized. Typically these will contain tables showing aggregate site specific glycoform distributions, example chromatograms and spectra, and statistical analyses used to compare batch-to-batch consistency. All of this information is required by regulatory agencies to assess the structure and quality of the product, understand control of the manufacturing process, and support claims of biosimilarity.
Technical limitations faced in the glycopeptide analysis of therapeutic antibodies include, but are not limited to, the complexity of the molecule itself and the vast microheterogeneity and range of glycosylation found. Considerations include sensitivity to detect minor populations, resolving structural isomers, data management, and ensuring consistency over time. Sample preparation, instrumentation, bioinformatics, and quality control all play important roles in ensuring proper characterization.
Detecting low-abundance glycoforms can be challenging when there is signal suppression by the high abundance glycoforms and limited dynamic range of the mass spectrometer. Glycoforms that are low abundance such as those containing sialic acid or rare glycans can be biologically significant and worth detecting. Methods such as enrichment via hydrophilic interaction chromatography or lectin affinity chromatography could be performed prior to detection to help enrich for low abundance glycans. Enrichment methods can bias the results or lead to loss of sample so it is important to make sure that low abundance glycoforms are enriched and recovered. Some glycoforms may only be present at low levels but can have immunogenicity or affect the pharmacokinetics of the protein.
Structurally differentiating linkage isomers, anomers, or epimers is challenging since they all have the same mass and elemental composition. Collision induced dissociation (CID) spectra typically do not yield fragment ions that can differentiate alpha and beta anomers or the linkages connecting monosaccharides. Fragmentation techniques like electron-transfer dissociation (ETD) can offer additional structural clues to differentiate isomers, but require additional hardware and are not always available. Separation on porous graphitic carbon columns and ion mobility can help differentiate these species, though it does not always fully resolve them. Standards and orthogonal methods are typically still needed for full structural characterization, making routine analysis of biomolecule pharmaceuticals containing multiple isomers difficult.
Data interpretation of glycopeptide mass spectrometry results is non-trivial and a challenge for bioinformatics. Glycopeptide ionization often results in multiple peaks per glycosylation site due to the mixture of glycoforms observed, different charge states of the glycopeptides, and possible adducts. Automated software identifying glycopeptides from MS data typically require validation as many permutations of glycan masses and peptide sequences will need to be searched resulting in many false positive matches. Once putative identifications have been made, manual validation of glycopeptide assignments also can be time-consuming due to the need for expert knowledge of glycan fragmentation. Software to merge datasets from multiple platforms (i.e. separate analysis of released glycans, intact proteins, and glycopeptides) is also needed. Furthermore, structure must be related to function which requires expertise in several fields including analytical chemistry, glycobiology, and immunology.
Table 3 Data Management Challenges
| Complexity Source | Impact on Analysis | Solution Strategy |
| Multiple glycoforms per site | Exponential increase in spectral features | Automated processing with manual verification |
| Charge state heterogeneity | Overlapping ion distributions | Deconvolution algorithms; high-resolution detection |
| False positive identification | Erroneous structural assignments | Score threshold optimization; orthogonal validation |
| Cross-platform integration | Difficulty correlating different data types | Standardized data formats; comprehensive databases |
Reproducibility between longitudinal experiments as well as between operators and instrumental platforms is challenging in glycopeptide analysis as glycosylation may be affected by even small changes in experimental conditions. Variations in sample processing, including digestion or enrichment recovery and storage conditions can change the relative abundance of observed glycoforms. Shifts in chromatographic efficiency, mass calibration or fragmentation efficiency from day-to-day or between instruments can impact accurate comparison between experiments. Standard operating procedures, inclusion of quality control standards, and system suitability testing prior to running samples can help control sources of variation. Most often variability in glycosylation is greater between biological samples (eg. different manufacturing lots, or cell culture conditions) than within.
Selecting the right analytical partner for monoclonal antibody (mAb) glycopeptide analysis is critical to ensuring data accuracy, regulatory compliance, and strategic development success. Antibody glycosylation is not merely a structural attribute—it is a recognized Critical Quality Attribute (CQA) that directly impacts biological function, comparability, and approval pathways. Our team combines deep regulatory understanding, advanced analytical platforms, and practical CMC experience to deliver reliable, development-stage-appropriate glycopeptide characterization that supports both innovator and biosimilar programs.
Our glycopeptide analysis services are designed with full awareness of global regulatory expectations for structural characterization of therapeutic antibodies. We understand how site-specific Fc glycosylation data fits within the broader Chemistry, Manufacturing, and Controls (CMC) framework. We support clients by:
Our reports are structured to integrate directly into regulatory documentation, reducing review cycles and strengthening submission readiness.
Monoclonal antibodies require specialized analytical strategies due to their structural complexity and Fc-specific glycosylation patterns. Our team consists of scientists with extensive experience in antibody characterization, glycopeptide LC-MS/MS method development, and functional correlation studies. Our expertise includes:
By combining high-resolution mass spectrometry with rigorous manual data validation, we ensure accurate site occupancy and microheterogeneity characterization for IgG1, IgG2, IgG4, bispecific antibodies, and Fc-fusion proteins.
No two antibody development programs are identical. We tailor each glycopeptide analysis study based on the molecule type, development stage, regulatory strategy, and risk profile. For innovator biologics, we support:
For biosimilar programs, we provide:
Our flexible study design ensures that analytical depth aligns with development needs—avoiding both under-characterization and unnecessary over-analysis.
Biopharmaceutical development operates under strict timelines, especially during biosimilar analytical similarity assessments or pre-IND submission preparation. We prioritize clear communication, predictable scheduling, and proactive regulatory alignment throughout every project. Clients benefit from:
From feasibility assessment to final technical reporting, we provide not only data, but strategic analytical support that accelerates decision-making and reduces development risk.
References
